Source link : https://newshealth.biz/health-news/fda-expands-use-of-t-dxd-in-early-her2-breast-cancer/
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-expands-use-t-dxd-early-her2-breast-cancer-2026a1000g1n?src=rss Author : Publish date : 2026-05-18 16:02:00 Copyright for syndicated content belongs to the linked Source.
The post FDA Expands Use of T-DXd in Early HER2+ Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-18 16:02:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8